Gold therapy has played a major role in the longterm management of rheumatoid arthritis (RA) for almost 60 years. Historically, gold salts were given to the patient by intramuscular injection. Recently an oral gold preparation, auranofin (triethylphosphine gold, Ridaura), has become available for use in patients on an experimental basis.
In adults about 25%'Y of the administered dose of auranofin is absorbed by the gastrointestinal tract and the half-life in the blood is approximately 21 days.' Auranofin has been found to possess definite antirheumatic properties in adult patients with RA during double-blind, controlled trials.2 In RA patients given auranofin 3 mg twice a day (approximately 0-1 mg/kg/day) a gradual increase in the blood gold concentration was observed until the twelfth week of therapy, at which time an average level of approximately 0 7 g.g of gold/ml of blood was attained. 4 To be included in the study patients had to meet a number of criteria. These included: (1) fulfilment of the American Rheumatism Association criteria for a diagnosis of JRA7; (2) age between 12 and 17 years; (3) active disease not adequately controlled by NSAID alone; (4) no previous gold therapy; and (5) no steroids or slower acting antirheumatic drugs for the 3-month period immediately prior to entering the study.
In addition all patients had to have either progressive limitation of joint motion or erosive arthritis. The monitoring and follow-up of patients and monitoring for adverse reactions was as described in the Pediatric Rheumatology Collaborative Study Group (PRCSG) guidelines.8 All patients were assessed for clinical and laboratory evidence of disease activity 2 weeks prior to the initiation of auranofin therapy, at the time therapy was begun, and at monthly intervals for the remainder of the study.
Heparinised venous blood samples were collected and sent to Smith, Kline and French Laboratories in Philadelphia for ascertainment of gold content.
GOLD ASSAY
Gold levels were determined by graphite furnace atomic absorption spectrophotometric technique." The specificity and versatility of similar techniques in the measurement of gold in biological material has been described elsewhere."-"3 The samples were digested by boiling in nitric and perchloric acid. They were then extracted in 25 ml of 10% (v/v) that steady state was reached in the majority of these children by at least 80 to 90 days and perhaps even earlier in some. In the 11 patients who had blood samples obtained between 11 and 13 weeks while at a constant dosage of 0-1 mg/kg/day the average steady state concentration was 0 51 gg/ml of blood (SEM = 0-044). In addition at a constant dosage the concentrations remained virtually unchanged.
In all cases increasing or decreasing the dosage of auranofin resulted in a corresponding change in blood gold concentration. As we have reported previously,6 patients who received the higher dose tended to do better with respect to clinical improvement and laboratory parameters of disease activity. Owing to the uncontrolled nature of this trial and the lack of uniformity in regard to the time at which blood samples were obtained for assay of gold content no effort has been made to correlate directly blood gold concentration with therapeutic efficacy.
Discussion
Data from the current study are remarkably similar to those obtained from studies of auranofin's pharmacokinetics in adults.' It appears that auranofin produces much more constant blood gold levels than do parenterally administered gold salts."4 However, the therapeutic consequences of this observation remain to be assessed. Moreover blood gold concentrations resulting from injectable gold are many times higher than those obtained with oral auranofin. However, it is well established that gold concentrations resulting from parenterally administered compounds correlate poorly with clinical efficacy.5-'7 A possible explanation for this lack of correlation is that the minimum, or threshold concentration at which gold becomes effective may have been exceeded many fold in these patients, and changes above this threshold have little impact on therapeutic outcome. Possibly some measureable lower boundary for efficacy exists in auranofin treated patients in whom steady state concentrations are measured in units as small as tenths of micrograms per millilitre of blood.
Animal and adult human studies of auranofin indicate that the chemical and physical properties, invivo distribution, and pharmacological mechanisms of action differ from those of the injectable gold compounds now in use... 1819 Thus the search for a minimum therapeutic range of blood gold concentration resulting from auranofin should not be immediately disregarded. We are unaware of published studies that have attempted to establish such a minimum therapeutic level in the adult. If such data do become available for RA, generalisation to JRA will probably not be possible, since it may be argued that, although the articular manifestations are similar, the underlying disease processes may be different. It will be necessary to study children with JRA treated with auranofin for minimum therapeutic levels, preferably in a double-blind trial. 
